Cargando…
Immunotherapy of targeting MDSCs in tumor microenvironment
Myeloid-derived suppressor cells (MDSCs) are a group of heterogeneous cells which are abnormally accumulated during the differentiation of myeloid cells. Immunosuppression is the main functional feature of MDSCs, which inhibit T cell activity in the tumor microenvironment (TME) and promote tumoral i...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484521/ https://www.ncbi.nlm.nih.gov/pubmed/36131911 http://dx.doi.org/10.3389/fimmu.2022.990463 |
_version_ | 1784791893606924288 |
---|---|
author | Sui, Hongshu Dongye, Shengyi Liu, Xiaocui Xu, Xinghua Wang, Li Jin, Christopher Q. Yao, Minhua Gong, Zhaoqing Jiang, Daniel Zhang, Kexin Liu, Yaling Liu, Hui Jiang, Guomin Su, Yanping |
author_facet | Sui, Hongshu Dongye, Shengyi Liu, Xiaocui Xu, Xinghua Wang, Li Jin, Christopher Q. Yao, Minhua Gong, Zhaoqing Jiang, Daniel Zhang, Kexin Liu, Yaling Liu, Hui Jiang, Guomin Su, Yanping |
author_sort | Sui, Hongshu |
collection | PubMed |
description | Myeloid-derived suppressor cells (MDSCs) are a group of heterogeneous cells which are abnormally accumulated during the differentiation of myeloid cells. Immunosuppression is the main functional feature of MDSCs, which inhibit T cell activity in the tumor microenvironment (TME) and promote tumoral immune escape. The main principle for immunotherapy is to modulate, restore, and remodel the plasticity and potential of immune system to have an effective anti-tumor response. In the TME, MDSCs are major obstacles to cancer immunotherapy through reducing the anti-tumor efficacy and making tumor cells more resistant to immunotherapy. Therefore, targeting MDSCs treatment becomes the priority of relevant studies and provides new immunotherapeutic strategy for cancer treatment. In this review, we mainly discuss the functions and mechanisms of MDSCs as well as their functional changes in the TME. Further, we review therapeutic effects of immunotherapy against MDSCs and potential breakthroughs regarding immunotherapy targeting MDSCs and immune checkpoint blockade (ICB) immunotherapy. |
format | Online Article Text |
id | pubmed-9484521 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94845212022-09-20 Immunotherapy of targeting MDSCs in tumor microenvironment Sui, Hongshu Dongye, Shengyi Liu, Xiaocui Xu, Xinghua Wang, Li Jin, Christopher Q. Yao, Minhua Gong, Zhaoqing Jiang, Daniel Zhang, Kexin Liu, Yaling Liu, Hui Jiang, Guomin Su, Yanping Front Immunol Immunology Myeloid-derived suppressor cells (MDSCs) are a group of heterogeneous cells which are abnormally accumulated during the differentiation of myeloid cells. Immunosuppression is the main functional feature of MDSCs, which inhibit T cell activity in the tumor microenvironment (TME) and promote tumoral immune escape. The main principle for immunotherapy is to modulate, restore, and remodel the plasticity and potential of immune system to have an effective anti-tumor response. In the TME, MDSCs are major obstacles to cancer immunotherapy through reducing the anti-tumor efficacy and making tumor cells more resistant to immunotherapy. Therefore, targeting MDSCs treatment becomes the priority of relevant studies and provides new immunotherapeutic strategy for cancer treatment. In this review, we mainly discuss the functions and mechanisms of MDSCs as well as their functional changes in the TME. Further, we review therapeutic effects of immunotherapy against MDSCs and potential breakthroughs regarding immunotherapy targeting MDSCs and immune checkpoint blockade (ICB) immunotherapy. Frontiers Media S.A. 2022-09-05 /pmc/articles/PMC9484521/ /pubmed/36131911 http://dx.doi.org/10.3389/fimmu.2022.990463 Text en Copyright © 2022 Sui, Dongye, Liu, Xu, Wang, Jin, Yao, Gong, Jiang, Zhang, Liu, Liu, Jiang and Su https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Sui, Hongshu Dongye, Shengyi Liu, Xiaocui Xu, Xinghua Wang, Li Jin, Christopher Q. Yao, Minhua Gong, Zhaoqing Jiang, Daniel Zhang, Kexin Liu, Yaling Liu, Hui Jiang, Guomin Su, Yanping Immunotherapy of targeting MDSCs in tumor microenvironment |
title | Immunotherapy of targeting MDSCs in tumor microenvironment |
title_full | Immunotherapy of targeting MDSCs in tumor microenvironment |
title_fullStr | Immunotherapy of targeting MDSCs in tumor microenvironment |
title_full_unstemmed | Immunotherapy of targeting MDSCs in tumor microenvironment |
title_short | Immunotherapy of targeting MDSCs in tumor microenvironment |
title_sort | immunotherapy of targeting mdscs in tumor microenvironment |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484521/ https://www.ncbi.nlm.nih.gov/pubmed/36131911 http://dx.doi.org/10.3389/fimmu.2022.990463 |
work_keys_str_mv | AT suihongshu immunotherapyoftargetingmdscsintumormicroenvironment AT dongyeshengyi immunotherapyoftargetingmdscsintumormicroenvironment AT liuxiaocui immunotherapyoftargetingmdscsintumormicroenvironment AT xuxinghua immunotherapyoftargetingmdscsintumormicroenvironment AT wangli immunotherapyoftargetingmdscsintumormicroenvironment AT jinchristopherq immunotherapyoftargetingmdscsintumormicroenvironment AT yaominhua immunotherapyoftargetingmdscsintumormicroenvironment AT gongzhaoqing immunotherapyoftargetingmdscsintumormicroenvironment AT jiangdaniel immunotherapyoftargetingmdscsintumormicroenvironment AT zhangkexin immunotherapyoftargetingmdscsintumormicroenvironment AT liuyaling immunotherapyoftargetingmdscsintumormicroenvironment AT liuhui immunotherapyoftargetingmdscsintumormicroenvironment AT jiangguomin immunotherapyoftargetingmdscsintumormicroenvironment AT suyanping immunotherapyoftargetingmdscsintumormicroenvironment |